Richard Gaynor

Last updated

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine (Los Angeles, CA) for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. [1] [2] His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. [3] [4] [5] [6] He has been a top executive at several pharmaceutical companies, [7] with respect to the development and clinical testing of novel anticancer drugs and cell therapies. [8] [9] For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. [10] Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. [11] [12] His honors include being elected a member of the American Society for Clinical Investigation, [13] and the Association of American Physicians. [14]

Contents

Education

In 1971 Gaynor graduated with a BS in Biology from Texas Tech University (Lubbock, TX). In 1975, he graduated with an MD from the University of Texas Southwestern Medical School (Dallas, TX). [1] [2] This was followed by internship (1975-1976) and residency (1976-1978) in internal medicine at Parkland Memorial Hospital (Dallas, TX). [1] [2] From 1978 to 1981 he was a Fellow at the Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine (Los Angeles, CA). TX). [1] [2] [15]

Career

In 1982 Gaynor became an Assistant Professor of Medicine at the Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine (Los Angeles, CA), where he further became an Associate Professor of Medicine in 1988 to 1991. [1] [2] [15] In 1991 he moved to the UT Southwestern Medical School (Dallas, TX), where he became Associate Professor of Medicine and Microbiology, Andrea L. Simmons Distinguished Chair in Cancer Virology, and Chief of the Division of Molecular Virology. At UT he further became a Full Professor and Chief of the Division of Hematology-Oncology in 1993, then interim Director (1997-1999), and Director of the Harold C. Simmons Comprehensive Cancer Center from 1999 to 2002. [16] During his time in Dallas, he was also a staff physician at the Dallas Veterans Affairs Medical Center, and an attending physician at Zale Lipshy University Hospital. [1] [2] [15]

In 2002, moved from UT and joined Eli Lilly and Company (Indianapolis, IN), where he remained until 2016, in positions as Vice President of Cancer Research and Clinical Investigation, and Senior Vice President of Global Oncology, Clinical and Product Development and Medical Affairs. [17] During his tenure at Lilly, the firm was involved in FDA approval of Gemcitabine for the treatment of ovarian cancer, [18] and directed clinical trials of Ramucirumab, Pemetrexed, Cetuximab, and Abemaciclib for a number of cancer treatment indications. [2]

He is the author of 140 publications indexed on Scopus (February 2022). [19] His research partly focused on the dysregulation of the nuclear factor NF-κB pathway in inflammation, autoimmunity, immunodeficiency, and neoplasia, and the options for its therapeutic targeting. [20] [21] His discoveries include the identification of IκB kinase as a second site of the anti-inflammatory action of aspirin. [22] His laboratory made noted insights into the regulation of retroviral gene expresión, [6] [23] some of which are referred on current entries on TAF1, MNAT1, and TARBP1. In 2014, he co-authored the AACR Cancer Progress Report. [24]

As a business executive, Gaynor was President of Research and Development at Neon Therapeutics, (Cambridge, MA) from 2016 to 2020. [11] Then, he became the President and Chief of Research and Development at BioNTech US (Cambridge, MA), his current position. [25] He is a member of the Board of Directors at Damon Runyon Cancer Research Foundation, [26] Alkermes PLC, [27] Infinity Pharmaceuticals, [28] and Zai Labs. [29] He is also a member of the Scientific Advisory Board at Leap Therapeutics. [30] He was also a member of technical boards of NPOs such as Damon Runyon Cancer Foundation, Walther Cancer Foundation the American Association for Cancer Research, and Stand Up to Cancer. [31]

Works

Research papers

Some of Gaynor's most cited research papers are: [32]

Related Research Articles

<span class="mw-page-title-main">NF-κB</span> Nuclear transcriptional activator that binds to enhancer elements in many different cell types

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a protein complex that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory.

<span class="mw-page-title-main">Richard Pestell</span> Australian oncologist and endocrinologist

Richard G. Pestell is an Australian American oncologist and endocrinologist who is Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honours for distinguished service to medicine and medical education.

<span class="mw-page-title-main">IKBKG</span> Protein-coding gene in the species Homo sapiens

NF-kappa-B essential modulator (NEMO) also known as inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-γ) is a protein that in humans is encoded by the IKBKG gene. NEMO is a subunit of the IκB kinase complex that activates NF-κB. The human gene for IKBKG is located on the chromosome band Xq28. Multiple transcript variants encoding different isoforms have been found for this gene.

<span class="mw-page-title-main">CD27</span> Member of the tumor necrosis factor receptor superfamily.

CD27 is a member of the tumor necrosis factor receptor superfamily. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule, and is the target of an anti-cancer drug in clinical trials.

<span class="mw-page-title-main">IKK2</span> Protein-coding gene in the species Homo sapiens

IKK-β also known as inhibitor of nuclear factor kappa-B kinase subunit beta is a protein that in humans is encoded by the IKBKB gene.

The IκB kinase is an enzyme complex that is involved in propagating the cellular response to inflammation, specifically the regulation of lymphocytes.

<span class="mw-page-title-main">IκBα</span> Protein-coding gene in the species Homo sapiens

IκBα is one member of a family of cellular proteins that function to inhibit the NF-κB transcription factor. IκBα inhibits NF-κB by masking the nuclear localization signals (NLS) of NF-κB proteins and keeping them sequestered in an inactive state in the cytoplasm. In addition, IκBα blocks the ability of NF-κB transcription factors to bind to DNA, which is required for NF-κB's proper functioning.

<span class="mw-page-title-main">RELA</span> Protein-coding gene in the species Homo sapiens

Transcription factor p65 also known as nuclear factor NF-kappa-B p65 subunit is a protein that in humans is encoded by the RELA gene.

<span class="mw-page-title-main">CHUK</span> Protein-coding gene in the species Homo sapiens

Inhibitor of nuclear factor kappa-B kinase subunit alpha (IKK-α) also known as IKK1 or conserved helix-loop-helix ubiquitous kinase (CHUK) is a protein kinase that in humans is encoded by the CHUK gene. IKK-α is part of the IκB kinase complex that plays an important role in regulating the NF-κB transcription factor. However, IKK-α has many additional cellular targets, and is thought to function independently of the NF-κB pathway to regulate epidermal differentiation.

<span class="mw-page-title-main">MAP3K14</span> Protein-coding gene in the species Homo sapiens

Mitogen-activated protein kinase kinase kinase 14 also known as NF-kappa-B-inducing kinase (NIK) is an enzyme that in humans is encoded by the MAP3K14 gene.

<span class="mw-page-title-main">TANK-binding kinase 1</span> Protein-coding gene in the species Homo sapiens

TBK1 is an enzyme with kinase activity. Specifically, it is a serine / threonine protein kinase. It is encoded by the TBK1 gene in humans. This kinase is mainly known for its role in innate immunity antiviral response. However, TBK1 also regulates cell proliferation, apoptosis, autophagy, and anti-tumor immunity. Insufficient regulation of TBK1 activity leads to autoimmune, neurodegenerative diseases or tumorigenesis.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of tumors. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

<span class="mw-page-title-main">Celastrol</span> Chemical compound

Celastrol (tripterine) is a chemical compound isolated from the root extracts of Tripterygium wilfordii and Tripterygium regelii. Celastrol is a pentacyclic nortriterpen quinone and belongs to the family of quinone methides. In mice, celastrol is an NR4A1 agonist that alleviates inflammation and induces autophagy. Also in mice, celastrol increase expression of IL1R1, which is the receptor for the cytokine interleukin-1 (IL-1). IL1R1 knock-out mice exposed to celastrol exhibit no leptin-sensitizing or anti-obesity effect.

Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies. In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance.

<span class="mw-page-title-main">NFKBID</span> Protein-coding gene in the species Homo sapiens

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta also known as IκBNS is a protein in humans that is encoded by the NFKBID gene.

The interleukin-1 receptor (IL-1R) associated kinase (IRAK) family plays a crucial role in the protective response to pathogens introduced into the human body by inducing acute inflammation followed by additional adaptive immune responses. IRAKs are essential components of the Interleukin-1 receptor signaling pathway and some Toll-like receptor signaling pathways. Toll-like receptors (TLRs) detect microorganisms by recognizing specific pathogen-associated molecular patterns (PAMPs) and IL-1R family members respond the interleukin-1 (IL-1) family cytokines. These receptors initiate an intracellular signaling cascade through adaptor proteins, primarily, MyD88. This is followed by the activation of IRAKs. TLRs and IL-1R members have a highly conserved amino acid sequence in their cytoplasmic domain called the Toll/Interleukin-1 (TIR) domain. The elicitation of different TLRs/IL-1Rs results in similar signaling cascades due to their homologous TIR motif leading to the activation of mitogen-activated protein kinases (MAPKs) and the IκB kinase (IKK) complex, which initiates a nuclear factor-κB (NF-κB) and AP-1-dependent transcriptional response of pro-inflammatory genes. Understanding the key players and their roles in the TLR/IL-1R pathway is important because the presence of mutations causing the abnormal regulation of Toll/IL-1R signaling leading to a variety of acute inflammatory and autoimmune diseases.

<span class="mw-page-title-main">WAY-204688</span> Chemical compound

WAY-204688, also known as SIM-688, is a synthetic nonsteroidal estrogen and nuclear factor κB (NF-κB) inhibitor which was originated by ArQule and Wyeth and was under development by Wyeth for the treatment of rheumatoid arthritis, non-specific inflammation, and sepsis but was never marketed. It is a "pathway-selective" estrogen receptor (ER) ligand which inhibits NF-κB with an IC50 of 122 nM and with maximal inhibition relative to estradiol of 94%. Inhibition of NF-κB by WAY-204688 appears to be dependent on agonism of the ERα, as it is reversed by the ERα antagonist fulvestrant, but is not dependent on the ERβ. In contrast to the case of NF-κB inhibition, WAY-204688 produces only slight elevation of creatine kinase in vitro, a measure of classical estradiol effects. It reached phase I clinical trials prior to the discontinuation of its development.

Ravi Salgia is an Indian-American oncologist who is the Arthur & Rosalie Kaplan Chair and Professor in Medical Oncology at the Comprehensive Cancer Center of City of Hope. Salgia serves on multiple National Cancer Institute panels. He has received research grants from the NIH for his work and has been granted several invention discoveries and patents concerning his research and became the Fellow of the Royal Society of Medicine. He has written 800 articles, reviews, and editorials with peer review, two books, and 34 book chapters.

<span class="mw-page-title-main">Nabil F. Saba</span> Atlanta oncologist

Nabil F. Saba is an American oncologist. He is currently Professor and Vice-chair of Hematology and Medical Oncology, and Professor of Otolaryngology at the Winship Cancer Institute at the Emory University School of Medicine in Atlanta, Georgia. He is a specialist in the field of head and neck oncology. Saba has authored more than 200 peer-reviewed articles. He is the inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research.

<span class="mw-page-title-main">Hypohidrotic ectodermal dysplasia with immune deficiency</span> Medical condition

Hypohidrotic/anhidrotic ectodermal dysplasia with immune deficiency is a rare genetic condition characterized by a combination of the features of ectodermal dysplasia alongside immunodeficiency.

References

  1. 1 2 3 4 5 6 "Richard B. Gaynor, MD". American Association for Cancer Research (AACR). Retrieved 2022-02-27.
  2. 1 2 3 4 5 6 7 "Richard B. Gaynor, MD – Cancer Progress by Cello Health BioConsulting, Previously Defined Health" . Retrieved 2022-02-28.
  3. ↑ Tak, Paul P.; Firestein, Gary S. (2001-01-01). "NF-κB: a key role in inflammatory diseases". The Journal of Clinical Investigation. 107 (1): 7–11. doi:10.1172/JCI11830. ISSN   0021-9738. PMC   198552 . PMID   11134171.
  4. ↑ Li, Qiutang; Verma, Inder M. (2002-10-01). "NF-κB regulation in the immune system". Nature Reviews Immunology. 2 (10): 725–734. doi:10.1038/nri910. ISSN   1474-1733. PMID   12360211. S2CID   6962119.
  5. ↑ Hoffmann, Alexander; Levchenko, Andre; Scott, Martin L.; Baltimore, David (2002-11-08). "The IκB-NF-κB Signaling Module: Temporal Control and Selective Gene Activation". Science. 298 (5596): 1241–1245. Bibcode:2002Sci...298.1241H. doi:10.1126/science.1071914. PMID   12424381. S2CID   11834415.
  6. 1 2 Kingsman, Susan M.; Kingsman, Alan J. (1996-09-15). "The Regulation of Human Immunodeficiency Virus Type-1 Gene Expression". European Journal of Biochemistry. 240 (3): 491–507. doi: 10.1111/j.1432-1033.1996.0491h.x . ISSN   0014-2956. PMID   8856047.
  7. ↑ "9688.HK Company Profile & Executives - Zai Lab Ltd. - Wall Street Journal". www.wsj.com. Retrieved 2022-02-27.
  8. ↑ "New Data On The Combination Of Lilly's ALIMTA (pemetrexed) And Merck's KEYTRUD (pembrolizumab) Show A Near-Doubling Of Objective Response Rate Compared To Standard Of Care Alone In First-Line Metastatic Non-Small Cell Lung Cancer". www.clinicalleader.com. Retrieved 2022-02-27.
  9. ↑ "Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update". AP NEWS. 2021-12-17. Retrieved 2022-02-27.
  10. ↑ "Document". www.sec.gov. Retrieved 2022-02-27.
  11. 1 2 "Neon Therapeutics Appoints Dr. Richard Gaynor to President of Research and Development". www.businesswire.com. 2016-11-07. Retrieved 2022-02-27.
  12. ↑ Limited, Zai Lab (2021-11-22). "Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors". GlobeNewswire News Room (Press release). Retrieved 2022-02-27.
  13. ↑ "The American Society for Clinical Investigation" . Retrieved 2022-04-22.
  14. ↑ "Association of American Physicians". aap-online.org. Retrieved 2022-04-22.
  15. 1 2 3 "Richard Gaynor, MD - Eli Lilly Seminar | Princeton University Department of Chemistry". chemistry.princeton.edu. Retrieved 2022-02-27.
  16. ↑ "Hematology and Oncology Overview". www.utsouthwestern.edu. Retrieved 2022-02-28.
  17. ↑ "ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio | Eli Lilly and Company". investor.lilly.com. Retrieved 2022-02-27.
  18. ↑ "FDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment | Eli Lilly and Company". investor.lilly.com. Retrieved 2022-02-28.
  19. ↑ "Scopus preview - Gaynor, Richard B. - Author details - Scopus". www.scopus.com. Retrieved 2022-02-28.
  20. 1 2 Yamamoto, Y.; Gaynor, R. B. (2001-01-01). "Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer". The Journal of Clinical Investigation. 107 (2): 135–142. doi:10.1172/JCI11914. ISSN   0021-9738. PMC   199180 . PMID   11160126.
  21. 1 2 Yamamoto, Yumi; Gaynor, Richard B. (2004-02-01). "IkappaB kinases: key regulators of the NF-kappaB pathway". Trends in Biochemical Sciences. 29 (2): 72–79. doi:10.1016/j.tibs.2003.12.003. ISSN   0968-0004. PMID   15102433.
  22. ↑ Gee, Henry (1998-11-12). "The avatars of aspirin". Nature. doi:10.1038/news981112-2. ISSN   1476-4687.
  23. ↑ Stevens, Miguel; De Clercq, Erik; Balzarini, Jan (2006-09-01). "The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention". Medicinal Research Reviews. 26 (5): 595–625. doi:10.1002/med.20081. ISSN   0198-6325. PMC   7168390 . PMID   16838299.
  24. ↑ Arteaga, Carlos L.; Adamson, Peter C.; Engelman, Jeffrey A.; Foti, Margaret; Gaynor, Richard B.; Hilsenbeck, Susan G.; Limburg, Paul J.; Lowe, Scott W.; Mardis, Elaine R.; Ramsey, Scott; Rebbeck, Timothy R. (2014-10-01). "AACR Cancer Progress Report 2014". Clinical Cancer Research. 20 (19 Suppl): S1–S112. doi:10.1158/1078-0432.CCR-14-2123. ISSN   1557-3265. PMC   4666597 . PMID   25228531.
  25. ↑ "BioNTech US leadership". biontech.de.
  26. ↑ "Annual report 2018" (PDF). damonrunyon.org.
  27. ↑ "Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D. | Alkermes plc". investor.alkermes.com. Retrieved 2022-02-27.
  28. ↑ "Infinity Pharmaceuticals Augments Board of Directors with Appointment of Richard Gaynor, M.D. | Infinity Pharmaceuticals, Inc". investors.infi.com. Retrieved 2022-02-27.
  29. ↑ "Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors | Zai Lab Limited". ir.zailaboratory.com. Retrieved 2022-02-27.
  30. ↑ "About". Leap Therapeutics, Inc. Retrieved 2022-02-27.
  31. ↑ "Scientific Advisory Committee (SAC)" (PDF). standuptocancer.org.
  32. ↑ "richard gaynor". scholar.google.com. Retrieved 2022-02-23.
  33. ↑ Ou, S. H.; Wu, F.; Harrich, D.; García-Martínez, L. F.; Gaynor, R. B. (1995-06-01). "Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs". Journal of Virology. 69 (6): 3584–3596. doi:10.1128/JVI.69.6.3584-3596.1995. ISSN   0022-538X. PMC   189073 . PMID   7745706.
  34. ↑ Yin, Min-Jean; Yamamoto, Yumi; Gaynor, Richard B. (1998-11-01). "The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β". Nature. 396 (6706): 77–80. Bibcode:1998Natur.396...77Y. doi:10.1038/23948. ISSN   0028-0836. PMID   9817203. S2CID   204995692.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.